Koen Van Laere

List of Publications by Year
in descending order

202 papers	9,160 citations	53794 45 h-index	49909 87 g-index
212 all docs	212 docs citations	212 times ranked	11968 citing authors

#	Article	IF	Citations
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
2	[18]F‑flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology, 2010, 68, 319-329.	5.3	582
3	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
4	EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 2103-2110.	6.4	469
5	[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9800-9805.	7.1	300
6	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nature Communications, 2020, 11, 5838.	12.8	225
7	Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 39-51.	6.4	208
8	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. Journal of Nuclear Medicine, 2016, 57, 1316-1322.	5.0	161
9	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature, 2021, 590, 320-325.	27.8	148
10	Evaluation of Three MRI-Based Anatomical Priors for Quantitative PET Brain Imaging. IEEE Transactions on Medical Imaging, 2012, 31, 599-612.	8.9	140
11	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912.	6.4	134
12	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
13	Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18F]MK-9470 PET. NeuroImage, 2008, 39, 1533-1541.	4.2	117
14	[18F]MK‑9470 PET measurement of cannabinoid CB_1 receptor availability in chronic cannabis users. Addiction Biology, 2015, 20, 357-367.	2.6	117
15	Value of [18]Fluorodeoxyglucose–Positron-Emission Tomography in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 553.	9.0	111
16	Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo. Journal of Nuclear Medicine, 2010, 51, 1413-1417.	5.0	107
17	Role of the GLUT1 Glucose Transporter in Postnatal CNS Angiogenesis and Blood-Brain Barrier Integrity. Circulation Research, 2020, 127, 466-482.	4.5	103
18	Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. Journal of Nuclear Medicine, 2006, 47, 1858-66.	5.0	101

#	Article	IF	Citations
19	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
20	Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: A positron emission tomography study using [18F]fallypride. NeuroImage, 2011, 58, 1081-1089.	4.2	95
21	Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with ^{18}F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. Journal of Nuclear Medicine, 2019, 60, 107-114.	5.0	92
22	Clinical features of *TBK1* carriers compared with *C9orf72*, *GRN* and non-mutation carriers in a Belgian cohort. Brain, 2016, 139, 452-467.	7.6	86
23	In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain, 2011, 134, 1033-1040.	7.6	84
24	Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiology of Aging, 2012, 33, 620.e1-620.e8.	3.1	82
25	Brain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa. Biological Psychiatry, 2011, 70, 777-784.	1.3	78
26	Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. Journal of Nuclear Medicine, 2016, 57, 1436-1441.	5.0	77
27	Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiology of Aging, 2015, 36, 1543-1558.	3.1	75
28	Preclinical Evaluation of ^{18}F-JNJ64349311, a Novel PET Tracer for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 975-981.	5.0	72
29	Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 396-406.	6.4	72
30	Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2219-2227.	6.4	69
31	^{18}F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. Journal of Nuclear Medicine, 2019, 60, 683-690.	5.0	63
32	Relationship of Type 1 Cannabinoid Receptor Availability in the Human Brain to Novelty-Seeking Temperament. Archives of General Psychiatry, 2009, 66, 196.	12.3	61
33	No Association of Lower Hippocampal Volume With Alzheimer's Disease Pathology in Late-Life Depression. American Journal of Psychiatry, 2017, 174, 237-245.	7.2	59
34	[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3033-3046.	6.4	59
35	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
36	EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 434-442.	6.4	56

#	Article	IF	Citations
37	In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology, 2020, 95, e545-e553.	1.1	56
38	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
39	Differences in Metabolic Network Modulation Between Capsulotomy and Deep-Brain Stimulation for Refractory Obsessive-Compulsive Disorder. Journal of Nuclear Medicine, 2014, 55, 951-959.	5.0	55
40	[11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinsonâ€™s disease and healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2051-2064.	6.4	55
41	Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease. Movement Disorders, 2020, 35, 1977-1986.	3.9	52
42	Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients. PLoS ONE, 2015, 10, e0131486.	2.5	52
43	In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. European Neuropsychopharmacology, 2014, 24, 242-250.	0.7	51
44	Optimized In Vivo Detection of Dopamine Release Using ^{18}F-Fallypride PET. Journal of Nuclear Medicine, 2012, 53, 1565-1572.	5.0	49
45	Kinetic analysis of the cannabinoid-1 receptor PET tracer [18F]MK-9470 in human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 920-933.	6.4	48
46	PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nuclear Medicine and Biology, 2015, 42, 753-761.	0.6	48
47	Diagnostic value of cerebrospinal fluid AÎ² ratios in preclinical Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 75.	6.2	47
48	Retention of [18F]fluoride on reversed phase HPLC columns. Journal of Pharmaceutical and Biomedical Analysis, 2015, 111, 209-214.	2.8	46
49	The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1367-1376.	6.4	45
50	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of *C9orf72* Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	9.0	45
51	Quantification of ^{18}F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Testâ€“Retest Study in Human Brain. Journal of Nuclear Medicine, 2013, 54, 1285-1293.	5.0	43
52	Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1607-1608.	6.4	43
53	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. Journal of Nuclear Medicine, 2020, 61, 604-607.	5.0	42
54	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	3.9	42

#	Article	IF	Citations
55	Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 142-151.	6.4	41
56	Combined Striatal Binding and Cerebral Influx Analysis of Dynamic ^{11}C-Raclopride PET Improves Early Differentiation Between Multiple-System Atrophy and Parkinson Disease. Journal of Nuclear Medicine, 2010, 51, 588-595.	5.0	39
57	Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand ^{18}F-MK-9470 in Healthy Subjects. Journal of Nuclear Medicine, 2008, 49, 439-445.	5.0	38
58	Regional Accuracy of ZTE-Based Attenuation Correction in Static [18F]FDG and Dynamic [18F]PE2I Brain PET/MR. Frontiers in Physics, 2019, 7, .	2.1	38
59	Comparison of New Tau PET-Tracer Candidates With [^{18}F]T808 and [^{18}F]T807. Molecular Imaging, 2016, 15, 153601211562492.	1.4	37
60	Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 254-261.	6.4	36
61	Fatty Acid Amide Hydrolase Inhibition by JNJâ€42165279: A Multipleâ€Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers. Clinical and Translational Science, 2018, 11, 397-404.	3.1	36
62	Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1323-1336.	6.4	35
63	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	6.4	35
64	Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 799.	2.8	35
65	Association of central serotonin transporter availability and body mass index in healthy Europeans. European Neuropsychopharmacology, 2014, 24, 1240-1247.	0.7	34
66	Optimization of Multimodal Imaging of Mesenchymal Stem Cells Using the Human Sodium Iodide Symporter for PET and Cerenkov Luminescence Imaging. PLoS ONE, 2014, 9, e94833.	2.5	32
67	Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity inÂvivo in R6/2 Huntington mice. Neurobiology of Aging, 2014, 35, 2858-2869.	3.1	32
68	What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2. Journal of Nuclear Medicine, 2017, 58, 110-116.	5.0	31
69	Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study. NeuroImage, 2021, 232, 117877.	4.2	31
70	Functional brain changes underlying irritability in premanifest Huntington's disease. Human Brain Mapping, 2015, 36, 2681-2690.	3.6	30
71	Cerebral dopaminergic and glutamatergic transmission relate to different subjective responses of acute alcohol intake: an in vivo multimodal imaging study. Addiction Biology, 2018, 23, 931-944.	2.6	30
72	Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2398-2399.	6.4	30

#	Article	IF	Citations
73	Functional Changes in the Language Network in Response to Increased Amyloid β Deposition in Cognitively Intact Older Adults. Cerebral Cortex, 2016, 26, 358-373.	2.9	29
74	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	6.4	29
75	Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia. Neurobiology of Aging, 2018, 61, 82-92.	3.1	29
76	Approximating anatomically-guided PET reconstruction in image space using a convolutional neural network. NeuroImage, 2021, 224, 117399.	4.2	29
77	Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue. Molecular Imaging and Biology, 2020, 22, 444-452.	2.6	28
78	Bioluminescence imaging of stroke-induced endogenous neural stem cell response. Neurobiology of Disease, 2014, 69, 144-155.	4.4	27
79	3D Shape Perception in Posterior Cortical Atrophy: A Visual Neuroscience Perspective. Journal of Neuroscience, 2015, 35, 12673-12692.	3.6	27
80	Lower Limbic Metabotropic Glutamate Receptor 5 Availability in Alcohol Dependence. Journal of Nuclear Medicine, 2018, 59, 682-690.	5.0	27
81	Neuroinflammation and Its Association with Cognition, Neuronal Markers and Peripheral Inflammation after Chemotherapy for Breast Cancer. Cancers, 2021, 13, 4198.	3.7	27
82	A Quantitative Evaluation of Joint Activity and Attenuation Reconstruction in TOF PET/MR Brain Imaging. Journal of Nuclear Medicine, 2019, 60, 1649-1655.	5.0	26
83	Translation of HDAC6 PET Imaging Using [18F]EKZ-001–cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates. ACS Chemical Neuroscience, 2020, 11, 1093-1101.	3.5	26
84	Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease. Neurology, 2022, 98, .	1.1	26
85	Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1796-1806.	6.4	25
86	Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1913-1926.	6.4	24
87	What Has Neuroimaging Taught Us on the Neurobiology of Yoga? A Review. Frontiers in Integrative Neuroscience, 2020, 14, 34.	2.1	24
88	Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients. Journal of Nuclear Medicine, 2020, 61, 256-262.	5.0	24
89	Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. Alzheimer's Research and Therapy, 2021, 13, 75.	6.2	24
90	In Vivo Characterization and Dynamic Receptor Occupancy Imaging of TPA023B, an α2/α3/α5 Subtype Selective γ-Aminobutyric Acid–A Partial Agonist. Biological Psychiatry, 2008, 64, 153-161.	1.3	23

#	Article	IF	Citations
91	Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3. Frontiers in Neuroscience, 2016, 10, 431.	2.8	23
92	Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 163-172.	6.4	23
93	Parametric imaging and quantitative analysis of the PET amyloid ligand [18 F]flutemetamol. NeuroImage, 2015, 121, 184-192.	4.2	22
94	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. Frontiers in Pharmacology, 2016, 7, 88.	3.5	22
95	Cholinergic depletion and basal forebrain volume in primary progressive aphasia. NeuroImage: Clinical, 2017, 13, 271-279.	2.7	22
96	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. Journal of Nuclear Medicine, 2020, 61, 1621-1627.	5.0	22
97	Preclinical Evaluation and Quantification of ^{18}F-FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5. Journal of Nuclear Medicine, 2015, 56, 1954-1959.	5.0	21
98	Functional integration changes in regional brain glucose metabolism from childhood to adulthood. Human Brain Mapping, 2016, 37, 3017-3030.	3.6	21
99	Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2348-2357.	6.4	21
100	Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles. Molecular Imaging and Biology, 2020, 22, 173-180.	2.6	21
101	In vivo synaptic density relates to glucose metabolism at rest in healthy subjects, but is strongly modulated by regional differences. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 0271678X2098150.	4.3	21
102	Positive Association Between Limbic Metabotropic Glutamate Receptor 5 Availability and Novelty-Seeking Temperament in Humans: An ^{18}F-FPEB PET Study. Journal of Nuclear Medicine, 2016, 57, 1746-1752.	5.0	20
103	In vivo evidence for long-term vascular remodeling resulting from chronic cerebral hypoperfusion in mice. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 726-739.	4.3	20
104	Differential brain responses to gradual intragastric nutrient infusion and gastric balloon distension: A role for gut peptides?. NeuroImage, 2017, 144, 101-112.	4.2	20
105	Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 570-577.	1.7	19
106	Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer ^{18}F-FPEB in human brain. Synapse, 2016, 70, 153-162.	1.2	18
107	Glutamatergic Biomarkers for Cocaine Addiction: A Longitudinal Study Using MR Spectroscopy and mGluR5 PET in Self-Administering Rats. Journal of Nuclear Medicine, 2018, 59, 952-959.	5.0	18
108	Behavioral Symptoms in Premanifest Huntington Disease Correlate with Reduced Frontal CB$_1$R Levels. Journal of Nuclear Medicine, 2019, 60, 115-121.	5.0	18

#	Article	IF	Citations
109	Methods for Quantifying Neurotransmitter Dynamics in the Living Brain With PET Imaging. Frontiers in Physiology, 2020, 11, 792.	2.8	18
110	Age-related GABAergic differences in the primary sensorimotor cortex: A multimodal approach combining PET, MRS and TMS. NeuroImage, 2021, 226, 117536.	4.2	18
111	Positron emission tomography imaging of cerebral glucose metabolism and type 1 cannabinoid receptor availability during temporal lobe epileptogenesis in the amygdala kindling model in rhesus monkeys. Epilepsia, 2018, 59, 959-970.	5.1	17
112	Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 313-315.	6.4	17
113	The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging. EJNMMI Research, 2017, 7, 10.	2.5	16
114	Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 68.	6.2	16
115	Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2342-2357.	6.4	16
116	Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 596-611.	6.4	16
117	Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A. Nuclear Medicine and Biology, 2014, 41, 695-704.	0.6	15
118	Outcome after epilepsy surgery at the University Hospitals Leuven 1998–2012. Acta Neurologica Belgica, 2016, 116, 271-278.	1.1	15
119	Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2681-2690.	6.4	15
120	Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Molecular Psychiatry, 2022, 27, 4244-4251.	7.9	15
121	Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using ^{18}F-FDG PET/CT. Journal of Nuclear Medicine, 2015, 56, 1520-1526.	5.0	14
122	[18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP. Journal of Neurochemistry, 2016, 139, 897-906.	3.9	14
123	Abnormal dopamine transporter imaging in adult-onset Niemann-Pick disease type C. Parkinsonism and Related Disorders, 2017, 36, 107-108.	2.2	14
124	Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 3.	3.9	13
125	On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone. EJNMMI Research, 2018, 8, 34.	2.5	13
126	Electroconvulsive therapy response in late-life depression unaffected by age-related brain changes. Journal of Affective Disorders, 2019, 251, 114-120.	4.1	13

#	Article	IF	Citations
127	Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression. Scientific Reports, 2021, 11, 15981.	3.3	13
128	Single-photon emission tomography. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 241-250.	1.8	12
129	Molecular Imaging of Human Embryonic Stem Cells Stably Expressing Human PET Reporter Genes After Zinc Finger Nucleaseâ€"Mediated Genome Editing. Journal of Nuclear Medicine, 2017, 58, 1659-1665.	5.0	12
130	Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced Î±-synucleinopathy. Experimental Neurology, 2019, 320, 112964.	4.1	12
131	Estimation of Crystal Timing Properties and Efficiencies for the Improvement of (Joint) Maximum-Likelihood Reconstructions in TOF-PET. IEEE Transactions on Medical Imaging, 2020, 39, 952-963.	8.9	12
132	Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. EJNMMI Research, 2021, 11, 41.	2.5	12
133	Changes in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study. Journal of Cerebral Blood Flow and Metabolism, 2021, , 0271678X2110477.	4.3	12
134	Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease. Movement Disorders, 2022, 37, 1883-1892.	3.9	12
135	Face shape and face identity processing in behavioral variant fronto-temporal dementia: A specific deficit for familiarity and name recognition of famous faces. NeuroImage: Clinical, 2016, 11, 368-377.	2.7	11
136	Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. European Radiology, 2022, 32, 901-911.	4.5	11
137	Phosphoâ€specific plasma pâ€tau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 734-746.	3.7	11
138	Excitotoxic neurodegeneration is associated with a focal decrease in metabotropic glutamate receptor type 5 availability: an in vivo PET imaging study. Scientific Reports, 2019, 9, 12916.	3.3	10
139	Brain metabolic changes across Kingâ€™s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1124-1133.	6.4	10
140	Regional glucose metabolic decreases with ageing are associated with microstructural white matter changes: a simultaneous PET/MR study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 664-680.	6.4	10
141	The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimerâ€™s disease. Science Translational Medicine, 2022, 14, eabg3684.	12.4	10
142	Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1236-1246.	4.3	10
143	Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease. Movement Disorders, 2017, 32, 943-945.	3.9	9
144	Changes in the language system as amyloid-Î² accumulates. Brain, 2021, 144, 3756-3768.	7.6	9

#	Article	IF	Citations
145	Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector. Journal of Visualized Experiments, 2016, , 53670.	0.3	8
146	The Role of Amyloid PET in Diagnosing Possible Transmissible Cerebral Amyloid Angiopathy in Young Adults with a History of Neurosurgery: A Case Series. Cerebrovascular Diseases, 2021, 50, 356-360.	1.7	8
147	Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature. EJNMMI Research, 2022, 12, 28.	2.5	8
148	FDG-PET findings in three cases of Mills' syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 87, jnnp-2014-309952.	1.9	7
149	IC-P-173: Utility of PMOD Image Quantification Software for Processing [^{11}C]PIB and [^{18}F]Flutemetamol Images for SUVR Quantitation on The Centiloid Scale. Alzheimer's and Dementia, 2016, 12, P126.	0.8	7
150	Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 533-547.	6.4	7
151	Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. EJNMMI Research, 2018, 8, 110.	2.5	7
152	Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of ^{177}Lu-DOTATATE PRRT. Acta Oncológica, 2020, 59, 644-651.	1.8	7
153	The Leuven late life depression (L3D) study: PET-MRI biomarkers of pathological brain ageing in late-life depression: study protocol. BMC Psychiatry, 2021, 21, 64.	2.6	7
154	Long-term Ashtanga yoga practice decreases medial temporal and brainstem glucose metabolism in relation to years of experience. EJNMMI Research, 2020, 10, 50.	2.5	7
155	Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function. Scientific Reports, 2021, 11, 16172.	3.3	6
156	Is there a glucose metabolic signature of spreading TDP-43 pathology in amyotrophic lateral sclerosis?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 96-104.	0.7	6
157	An optimized MRI and PET based clinical protocol for improving the differential diagnosis of geriatric depression and Alzheimer's disease. Psychiatry Research - Neuroimaging, 2022, 320, 111443.	1.8	6
158	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers: Figure 1. Brain, 2015, 138, e350-e350.	7.6	5
159	Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson's disease using 18F-FDG PET imaging. Scientific Reports, 2019, 9, 12368.	3.3	5
160	Rigid motion tracking using moments of inertia in TOF-PET brain studies. Physics in Medicine and Biology, 2021, 66, 184001.	3.0	5
161	Neuroinflammation as potential precursor of leukoencephalopathy in early-stage breast cancer patients: A cross-sectional PET-MRI study. Breast, 2022, 62, 61-68.	2.2	5
162	Asymmetric Amyloid Deposition in the Brain Following Unilateral Electroconvulsive Therapy. Biological Psychiatry, 2017, 81, e11-e13.	1.3	4

#	Article	IF	Citations
163	Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain. EJNMMI Research, 2018, 8, 112.	2.5	4
164	Predictive value of metabolic and perfusion changes outside the seizure onset zone for postoperative outcome in patients with refractory focal epilepsy. Acta Neurologica Belgica, 2021, , 1.	1.1	4
165	Estimation of crystal timings in TOF-PET. , 2018, , .		3
166	ICâ€Pâ€150: [Câ€11]MKâ€6884 PET: CHARACTERIZING BRAIN M4 RECEPTORS IN HEALTHY ELDERLY VOLUNTEERS AND ACETYLCHOLINESTERASE INHIBITORSâ€TREATED AD PATIENTS. Alzheimer's and Dementia, 2019, 15, P121.	0.8	3
167	Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density. EJNMMI Physics, 2021, 8, 37.	2.7	3
168	Twelve-Week Yoga vs. Aerobic Cycling Initiation in Sedentary Healthy Subjects: A Behavioral and Multiparametric Interventional PET/MR Study. Frontiers in Psychiatry, 2021, 12, 739356.	2.6	3
169	Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18Fâ€"FDG-PET/CT. BMC Cancer, 2018, 18, 253.	2.6	2
170	Assessment of in vivo bone activity patterns in medial mobile-bearing unicompartmental knee arthroplasty. Bone and Joint Journal, 2022, 104-B, 34-44.	4.4	2
171	The Effect of Aging on Brain Glucose Metabolic Connectivity Revealed by [18F]FDG PET-MR and Individual Brain Networks. Frontiers in Aging Neuroscience, 2021, 13, 798410.	3.4	2
172	Cannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: A preliminary multitracer positron emission tomography study. Addiction Biology, 2022, 27, e13167.	2.6	2
173	ICâ€Pâ€187: Discovery and Firstâ€inâ€Human Evaluation of the TAUâ€imaging PET Radiotracer [18F]MKâ€6240. Alzheimer's and Dementia, 2016, 12, P136.	0.8	1
174	Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging. Journal of Nuclear Medicine, 2021, 62, 1318-1319.	5.0	1
175	Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 492-502.	6.4	1
176	Interhemispheric metabolic asymmetries in patients with anti-NMDA receptor encephalitis. Acta Neurologica Belgica, 2021, 121, 1385-1387.	1.1	1
177	Rigid Motion Tracking using Moments of Inertia in TOF-PET Brain Studies. , 2020, , .		1
178	Influence of medication and PTH levels on detection of parathyroid adenomas with dual isotope parathyroid scintigraphy. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 207-217.	1.0	1
179	Clinical implications of fever at diagnosis in polymyalgia rheumatica: an age- and sex-matched case control study of 120 patients. Clinical and Experimental Rheumatology, 2022, 40, 193-194.	0.8	1
180	Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	6.4	1

#	Article	IF	Citations
181	O2-10-03: In vivo characterization of basal forebrain atrophy and cholinergic denervation in primary progressive aphasia. , 2015, 11, P198-P198.		0
182	P1-350: 3D-Shape Perception in Amnestic Mild Cognitive Impairment. , 2016, 12, P563-P564.		0
183	P1-319: The Effect of Gray Matter Volume and Amyloid Load on Normal Cognitive Performance in Cognitively Intact Older Adults. , 2016, 12, P547-P547.		0
184	P1-246: Discovery and First-in-Human Evaluation of the TAU-Imaging PET Radiotracer [18 F]MK-6240. , 2016, 12, P501-P502.		0
185	[P3â€"385]: VISUAL READING OF AMYLOIDâ€PET IN MCI CHALLENGED: SHOULD WE CONSIDER ALTERNATIVE METHODS?. Alzheimer's and Dementia, 2017, 13, P1107.	0.8	0
186	O3â€10â€03: A POLYGENIC AD RISK SCORE PREDICTS AMYLOID ACCUMULATION OVER A 6â€YEAR INTERVAL IN COGNITIVELY INTACT OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1041.	0.8	0
187	An approach for a reconstruction-derived whole-blood arterial input function (RDIF) in PET/MRI. , 2018, , .		0
188	Maximum Likelihood Estimation of the Geometric Sensitivities in PET. , 2019, , .		0
189	ICâ€Pâ€003: THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS. Alzheimer's and Dementia, 2019, 15, P14.	0.8	0
190	Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report. BMC Gastroenterology, 2020, 20, 324.	2.0	0
191	White matter brain lesions in infantile-onset Pompe disease are not metabolically active using 18F-FDG PET/MR imaging. Neuromuscular Disorders, 2020, 30, 732-733.	0.6	0
192	Regional distribution of amyloid deposition and grey matter atrophy in lateâ€life depression. Alzheimer's and Dementia, 2020, 16, e041564.	0.8	0
193	Differential involvement of limbic and paralimbic cortex in episodic memory processing in cognitive aging and neurodegeneration. Alzheimer's and Dementia, 2020, 16, e044516.	0.8	0
194	Longitudinal changes in [18 F]Flutemetamol load in cognitively intact APOE Îμ4 carriers vs noncarriers: Comparison of three reference regions. Alzheimer's and Dementia, 2020, 16, e044534.	0.8	0
195	Tau Pathology Associated With Parkinsonism and Mutation of Mitochondrial DNA Helicase Gene <i>TWNK</i>. Neurology: Genetics, 2021, 7, e620.	1.9	0
196	Comparison of kinetic modelling strategies of N-[11C]-methylpiperidin-4-yl-proprionate ([11C]-PMP) in normals and patients with mild cognitive impairment (MCI). Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S593-S593.	4.3	0
197	In vivo multimodal (MRI, SPECT) imaging of the 6-OHDA rat model for Parkinson's disease correlated with behavior and histology. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S392-S392.	4.3	0
198	Clinical implications of fever at diagnosis in polymyalgia rheumatica: an age- and sex-matched case control study of 120 patients. Clinical and Experimental Rheumatology, 2021, , .	0.8	0

#	Article	IF	Citations
199	Clinical implications of fever at diagnosis in polymyalgia rheumatica: an age- and sex-matched case control study of 120 patients. Reply to Milchert et al. and Manzo et al. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
200	Clinical implications of fever at diagnosis in polymyalgia rheumatica: an age- and sex-matched case control study of 120 patients. Reply to Milchert et al. and Manzo et al.. Clinical and Experimental Rheumatology, 2022, 40, 668-668.	0.8	0
201	Longitudinal changes in the brain language system as amyloid accumulates. Alzheimer's and Dementia, 2021, 17, .	0.8	0
202	Assessment of Alzheimer's disease polygenic risk score on longitudinal amyloid accumulation in cognitively intact older adults.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055201.	0.8	0